Board of Directors

Susannah Gray Former Executive Vice President, Finance & Strategy, Royalty Pharma Management

Susannah Gray brings more than 30 years of biopharmaceutical experience specifically in corporate finance and capital markets roles, most recently serving as EVP, Finance & Strategy of Royalty Pharma Management, LLC. Ms. Gray spent 14 years as Executive Vice President and Chief Financial Officer of Royalty Pharma before retiring in 2019 just ahead of the Company’s initial public offering. At Royalty Pharma, Ms. Gray led the Company’s efforts to maximize its financial capabilities. In her career at Royalty Pharma, she increased the debt facilities from approximately $200 million to $7 billion, and was responsible for over $20 billion in total financing. She also raised $2.0 billion equity capital for the Company.

Prior to joining Royalty Pharma, Ms. Gray had a 14-year career in investment banking. In her most recent role, she was a Managing Director and the Senior Analyst covering the healthcare sector for CIBC World Market’s high yield group from 2002 to 2004. She worked in a similar capacity at Merrill Lynch prior to joining CIBC World Markets. Ms. Gray joined Merrill Lynch in April 1999 after nine years at Chase Securities (a predecessor of JP Morgan), working in various capacities within the high yield and the structured finance groups. Ms. Gray received a BA with honors from Wesleyan University and holds an MBA degree from Columbia University. Ms. Gray currently serves on the board of directors of Susan G. Komen and is on the board of trustees at Wesleyan University.

Karen McGinnis Former Vice President and Chief Accounting Officer, Illumina

Karen McGinnis has served as a member of the Board of Directors since March 2021. Ms. McGinnis has over 30 years of experience in executive operational and finance roles at international public companies. She most recently served as Vice President & Chief Accounting Officer of Illumina, Inc., a leader in sequencing- and array-based solutions for genetic and genomic analysis from November 2017 until her retirement on April 2, 2021. Prior to joining Illumina, Ms. McGinnis served from February 2016 to April 2017 as Director, President and Chief Executive Officer of Mad Catz Interactive, Inc. a global provider of innovative interactive entertainment products. From June 2013 through February 2016, Ms. McGinnis served as Mad Catz’ Chief Financial Officer. Prior to joining Mad Catz, Ms. McGinnis served from November 2009 through May 2013 as Chief Accounting Officer of Cymer, Inc., the world’s leading supplier of light sources used in the photolithography process for semiconductor or chip manufacturing until its acquisition in 2013. Ms. McGinnis also served as Chief Accounting Officer for Insight Enterprises, Inc., from September 2006 until March 2009, its Senior Vice President of Finance from 2001 through September 2006 and its Vice President of Finance from 2000 through 2001. Ms. McGinnis also serves as a director of Alphatec Holdings, Inc. (Nasdaq: ATEC), Absci Corporation (Nasdaq: ABSI) and Sonendo, Inc. (NYSE: SONX). Ms. McGinnis is a Certified Public Accountant and earned her BBA in Accounting from the University of Oklahoma.

Board Observers

Xinhong Lim, PhD Assistant Managing Director, Vickers Venture Partners

Dr Xinhong Lim is a venture capital investor and award-winning scientist. He joined Vickers Venture Partners in 2015 and is based in Silicon Valley. He has led investments into companies in the life sciences, medical device, AI and advanced materials sectors, and advises on fund strategy in these areas. He serves as a director on the boards of Emergex (synthetic T-cell vaccines) and RWDC Industries (sustainable biopolymers), and as an observer on the boards of Aardvark (metabolic and inflammatory disease therapeutics), Lumitron (extremely brilliant Compton X-ray light sources), Sisaf (silicon-stabilized lipid nanoparticles for RNA delivery) and Biosplice (RNA-splicing modulatory therapeutics). He is Chief Strategy Officer of RWDC.

Dr Lim received his Ph.D. in Developmental Biology from Stanford University under the tutelage of Breakthrough Prize winner Professor Roel Nusse, a pioneer of Wnt signaling biology, and obtained a Certificate in Innovation and Entrepreneurship from the Stanford Graduate School of Business. He received a B.S. in Biochemistry from the University of Wisconsin-Madison, where he graduated with Highest Distinction. Dr Lim is an Assistant Professor (Adjunct) at the Skin Research Institute of Singapore (SRIS) and NTU LKC School of Medicine. He has served as an invited speaker for many international professional and scientific conferences and has been the principal investigator for more than $15 million of research grants. Dr Lim’s work has been published and cited in the most prestigious scientific journals, including Nature and Science, as well as highlighted in the international press, including by CNN and BBC. He is the recipient of numerous awards, including the Singapore National Academy of Sciences Young Scientist Award and the Ten Outstanding Young Singaporeans Award (Medical Innovation).